- Home
- AMGN vs SCHW Comparison
AMGN vs SCHW Comparison
Compare AMGN & SCHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- SCHW
- Stock Information
- Founded
- AMGN 1980
- SCHW 1971
- Country
- AMGN United States
- SCHW United States
- Employees
- AMGN N/A
- SCHW N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- SCHW Investment Bankers/Brokers/Service
- Sector
- AMGN Health Care
- SCHW Finance
- Exchange
- AMGN Nasdaq
- SCHW Nasdaq
- Market Cap
- AMGN 156.2B
- SCHW 133.5B
- IPO Year
- AMGN N/A
- SCHW 1987
- Fundamental
- Price
- AMGN $265.86
- SCHW $84.44
- Analyst Decision
- AMGN Buy
- SCHW Buy
- Analyst Count
- AMGN 19
- SCHW 15
- Target Price
- AMGN $324.37
- SCHW $88.73
- AVG Volume (30 Days)
- AMGN 2.7M
- SCHW 9.1M
- Earning Date
- AMGN 05-01-2025
- SCHW 04-17-2025
- Dividend Yield
- AMGN 3.58%
- SCHW 1.28%
- EPS Growth
- AMGN 56.16
- SCHW 38.09
- EPS
- AMGN 10.94
- SCHW 3.30
- Revenue
- AMGN $34,126,000,000.00
- SCHW $20,465,000,000.00
- Revenue This Year
- AMGN $7.19
- SCHW $17.66
- Revenue Next Year
- AMGN $2.37
- SCHW $10.59
- P/E Ratio
- AMGN $24.29
- SCHW $25.62
- Revenue Growth
- AMGN 15.56
- SCHW 10.86
- 52 Week Low
- AMGN $253.30
- SCHW $61.01
- 52 Week High
- AMGN $346.85
- SCHW $85.19
- Technical
- Relative Strength Index (RSI)
- AMGN 34.80
- SCHW 68.09
- Support Level
- AMGN $268.81
- SCHW $82.04
- Resistance Level
- AMGN $291.61
- SCHW $85.19
- Average True Range (ATR)
- AMGN 7.54
- SCHW 1.55
- MACD
- AMGN -0.76
- SCHW 0.56
- Stochastic Oscillator
- AMGN 0.76
- SCHW 92.32
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About SCHW Charles Schwab Corporation (The)
Charles Schwab operates in brokerage, wealth management, banking, and asset management. It runs a large network of brick-and-mortar brokerage branch offices and a well-established online investing website, and it has mobile trading capabilities. It also operates a bank and a proprietary asset-management business and offers services to independent investment advisors. Schwab is among the largest firms in the investment business, with over $10 trillion of client assets at the end of 2024. Nearly all of its revenue is from the United States.